Table 1.
Baseline Characteristics and Outcomes of ART Patients at Themba Lethu Clinic Stratified by Gender (n=7,354)
| |
Gender |
|
|
|---|---|---|---|
| Characteristic | Male (n=2,733) | Female (n=4,621) | Total (n=7,354) |
| Age, years | |||
| 18–24.9 | 49 (1.8%) | 274 (5.9%) | 323 (4.4%) |
| 25–29.9 | 252 (9.2%) | 747 (16.2%) | 999 (13.6%) |
| 30–39.9 | 1341 (49.1%) | 2090 (45.2%) | 3431 (46.7%) |
| 40–49.9 | 780 (28.5%) | 1129 (24.4%) | 1909 (25.9%) |
| >50 | 311 (11.4%) | 381 (8.3%) | 692 (9.4%) |
| CD4 at ART Initiation (cells/mm3) | |||
| 0–50 | 987 (36.1%) | 1330 (28.8%) | 2317 (31.5%) |
| 51–100 | 586 (21.4%) | 950 (20.6%) | 1536 (20.9%) |
| 101–200 | 887 (32.5%) | 1792 (38.8%) | 2679 (36.4%) |
| 201–350 | 228 (8.3%) | 480 (10.4%) | 708 (9.6%) |
| Missing | 45 (1.7%) | 69 (1.4%) | 114 (1.6%) |
| WHO stage at ART initiation | |||
| I/II | 1468 (53.7%) | 2750 (59.5%) | 4218 (57.4%) |
| III | 1057 (38.7%) | 1590 (34.4%) | 2647 (36.0%) |
| IV | 208 (7.6%) | 281 (6.1%) | 489 (6.6%) |
| First-line ART regimen | |||
| d4T/3TC/EFV | 2484 (90.9%) | 4143 (89.6%) | 6627 (90.1%) |
| d4T/3TC/NVP | 156 (5.7%) | 363 (7.9%) | 519 (7.0%) |
| AZT/3TC/EFV | 87 (3.2%) | 102 (2.2%) | 189 (2.6%) |
| AZT/3TC/NVP | 6 (0.2%) | 13 (0.3%) | 19 (0.3%) |
| CD4 at ART Initiation (cells/mm3) | |||
| Median (IQR) | 81 (29–151) | 100 (41–163) | 93 (36–159) |
| Time on ART (months) | |||
| Median (IQR) | 35.1 (19.5–53.9) | 35.8 (21.0–55.2) | 35.4 (20.3–54.7) |
| Hemoglobin at ART Initiation (μg/dL) | |||
| Median (IQR) | 12.5 (10.7–14.0) | 11.2 (9.8–12.5) | 11.7 (10.1–13.0) |
| BMI at ART Initiation | |||
| Median (IQR) | 20.4 (18.5–22.7) | 22.5 (19.7–25.9) | 21.6 (19.1–24.7) |
| Age at ART Initiation | |||
| Median (IQR) | 37.9 (33.3–43.9) | 35.8 (30.6–42.3) | 36.7 (31.6–43.0) |
| Outcomes | |||
| Death, n (%) | 143 (5.2) | 190 (4.1) | 333 (4.5) |
| Loss to follow-up, n (%) | 576 (21.1) | 806 (17.5) | 1382 (18.8) |
| Transferred, n (%) | 195 (7.1) | 403 (8.7) | 598 (8.1) |
| Alive and in care, n (%) | 1819 (66.6) | 3222 (69.7) | 5041 (68.6) |
ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; 3TC, lamivudine; WHO, World Health Organizations.